← Back to Clinical Trials
Recruiting NCT07087431
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Trial Parameters
Condition Coronary Artery Disease
Sponsor Massachusetts General Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age 30 Years
Max Age 75 Years
Start Date 2025-10-15
Completion 2026-10-15
Interventions
Immediate disclosure of CAD PRS resultsDeferred Disclosure of CAD PRS results
Brief Summary
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Eligibility Criteria
Inclusion Criteria: * Current age 30-75 years * Established primary care at Mass General Brigham with at least one visit in the last 2 years Exclusion Criteria: \- Currently taking LDL cholesterol- lowering medications, including statins